FDA wary of side effects of Tysabri for Crohn's disease

The FDA has expressed concern over possible fatal side effects from the use of Tysabri to treat Crohn's disease. The agency says it is concerned that taking Tysabri, already approved for multiple sclerosis, could lead to a rare and incurable nervous system disease.

View Full Article in:

Arizona Republic (Phoenix) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC